Cart
sales@molnova.com
Inarigivir ammonium
CAS No. 2172788-92-8
Inarigivir ammonium( ORI-9020 ammonium | SB-9200 ammonium )
Catalog No. M28733 CAS No. 2172788-92-8
Inarigivir ammonium is a dinucleotide antiviral compound that significantly reduces HBV DNA in transgenic mice expressing hepatitis B virus. Inarigivir is an agonist of retinoic acid-inducible gene-I (RIG-I) that activates intracellular innate immunity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 538 | Get Quote |
|
| 5MG | 860 | Get Quote |
|
| 10MG | 1161 | Get Quote |
|
| 25MG | 1728 | Get Quote |
|
| 50MG | 2331 | Get Quote |
|
| 100MG | 3132 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameInarigivir ammonium
-
NoteResearch use only, not for human use.
-
Brief DescriptionInarigivir ammonium is a dinucleotide antiviral compound that significantly reduces HBV DNA in transgenic mice expressing hepatitis B virus. Inarigivir is an agonist of retinoic acid-inducible gene-I (RIG-I) that activates intracellular innate immunity.
-
DescriptionInarigivir ammonium is a dinucleotide antiviral compound that significantly reduces HBV DNA in transgenic mice expressing hepatitis B virus. Inarigivir is an agonist of retinoic acid-inducible gene-I (RIG-I) that activates intracellular innate immunity.(In Vitro):Inarigivir is active against HBV variants carrying resistance markers against all the nucleos(t)ide analogues approved for treating chronic hepatitis B.(In Vivo):Administration of 100 mg/kg/day Inarigivir (ip) significantly reduces viral DNA in the liver and shows anti-HBV activity while serum HBV DNA is not reduced. Inarigivir does not affect levels of HBV RNA in liver, levels of HBeAg in serum, or mean titers of HBsAg. The minimal effective dose is identified to be between 1.6 and 0.5 mg/kg/day using liver HBV DNA values.
-
In VitroInarigivir (SB 9200) is active against HBV variants carrying resistance markers against all the nucleos(t)ide analogues approved for treating chronic hepatitis B.
-
In VivoInarigivir (100 mg/kg/day, ip) significantly reduces viral DNA in the liver and shows anti-HBV activity. Serum HBV DNA is not reduced in response to treatment. Inarigivir does not affect levels of HBV RNA in liver, levels of HBeAg in serum, or mean titers of HBsAg. The minimal effective dose is identified to be between 1.6 and 0.5 mg/kg/day using liver HBV DNA values. Animal Model:Mice Dosage:100 mg/kg.Administration:IP, daily.Result:Significantly reduced viral DNA in the liver and shows anti-HBV activity similar ADV positive control.
-
SynonymsORI-9020 ammonium | SB-9200 ammonium
-
PathwayMicrobiology/Virology
-
TargetHBV
-
RecptorHIF/HIF Prolyl-Hydroxylase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2172788-92-8
-
Formula Weight604.53
-
Molecular FormulaC20H29N8O10PS
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?H2O : 100 mg/mL (165.42 mM)
-
SMILESNC1=C(N=CN2[C@@H]3O[C@H](COP(O[C@H]4[C@@H](OC)[C@H](N5C=CC(NC5=O)=O)O[C@@H]4CO)(S)=O)[C@@H](O)C3)C2=NC=N1.N
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Nangaku M, et al. A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia. Arterioscler Thromb Vasc Biol. 2007 Dec;27(12):2548-54.
molnova catalog
related products
-
Hepatitis B Virus Co...
The hepatitis B virus (HBV) core protein has been found in the nucleus, the cytoplasm, or both of HBV-infected hepatocytes. nuclear localization of the HBV core protein is negatively regulated by phosphorylation during the cell cycle.
-
HBV Capsid inhibitor...
HBV Capsid inhibitor 3711 (Compound 3711) is a nonnucleosidic HBV inhibitor.
-
Burfiralimab
Burfiralimab (hzVSF-v13) is a monoclonal immunoglobulin (IgG4) targeted against waveform proteins, exhibiting anti-HBV properties and potential applications in rheumatoid arthritis research.
